CAMBRIDGE, Mass., June 23,
2022 /PRNewswire/ -- Blueprint Medicines Corporation
(NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr.
Dable, who was Chief Executive Officer of Acceleron Pharma from
2016 to 2021, brings nearly 30 years of experience in strategic
leadership, commercial growth and organizational scale across
global pharmaceutical and emerging biotechnology companies.
"Habib's experience leading global, complex organizations will
be incredibly valuable as Blueprint Medicines drives our next phase
of transformational growth," said Kate
Haviland, Chief Executive Officer. "We are thrilled to
welcome his significant expertise and perspective to our
board."
"Blueprint Medicines has an impressive track record for a
company of its size and age; even more impressive are the potential
opportunities that lie ahead across development and
commercialization," said Mr. Dable. "I look forward to working with
Blueprint's high caliber team to execute on these opportunities and
continue bringing the promise of precision medicine to broad
patient populations."
Mr. Dable joins Blueprint Medicines with significant leadership,
growth and commercial experience gained during nearly 30 years in
the biopharmaceutical industry. Most recently, as CEO at Acceleron,
Mr. Dable generated more than $10
billion in shareholder value over his 5-year tenure as CEO
before successfully transitioning to Merck following its
acquisition. Prior to joining Acceleron in 2016, Mr. Dable spent 22
years at Bayer AG. During his tenure at Bayer, Mr. Dable held
positions of increasing responsibility and geographic footprint,
including President of U.S. Pharmaceuticals; Executive Vice
President, Global Head Specialty Medicine; Vice President,
Ophthalmology; Global Launch Team Head, EYLEA®; Global Head,
Neurology and Ophthalmology; and Vice President, Regional Head,
Hematology and Cardiology. Recently, Mr. Dable served on the Board
of Directors of the Biotechnology Innovation Organization (BIO).
Mr. Dable received a B.B.A. in Marketing and Finance and his M.B.A.
from the University of New
Brunswick.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities,
to rapidly and reproducibly translate science into a broad pipeline
of precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer and other genomically defined cancers, and cancer
immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Blueprint Medicines' strategy, goals and anticipated
milestones, business plans and focus. The words "aim," "may,"
"will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "predict," "project," "potential,"
"continue," "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this report are based on management's
current expectations and beliefs and are subject to a number of
risks, uncertainties and important factors that may cause actual
events or results to differ materially from those expressed or
implied by any forward-looking statements contained in this report,
including, without limitation, risks and uncertainties related to
the impact of the COVID-19 pandemic to Blueprint Medicines'
business, operations, strategy, goals and anticipated milestones,
including Blueprint Medicines' ongoing and planned research and
discovery activities, ability to conduct ongoing and planned
clinical trials, clinical supply of current or future drug
candidates, commercial supply of current or future approved
products, and launching, marketing and selling current or future
approved products; Blueprint Medicines' ability and plans in
continuing to establish and expand a commercial infrastructure, and
successfully launching, marketing and selling current or future
approved products; Blueprint Medicines' ability to successfully
expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO or
obtain marketing approval for AYVAKIT/AYVAKYT in additional
geographies in the future; the delay of any current or planned
clinical trials or the development of Blueprint Medicines' current
or future drug candidates; Blueprint Medicines' advancement of
multiple early-stage efforts; Blueprint Medicines' ability to
successfully demonstrate the safety and efficacy of its drug
candidates and gain approval of its drug candidates on a timely
basis, if at all; the preclinical and clinical results for
Blueprint Medicines' drug candidates, which may not support further
development of such drug candidates either as monotherapies or in
combination with other agents or may impact the anticipated timing
of data or regulatory submissions; the timing of the initiation of
clinical trials and trial cohorts at clinical trial sites and
patient enrollment rates; actions of regulatory agencies, which may
affect the initiation, timing and progress of clinical trials;
Blueprint Medicines' ability to obtain, maintain and enforce patent
and other intellectual property protection for AYVAKIT/AYVAKYT,
GAVRETO or any drug candidates it is developing; Blueprint
Medicines' ability to develop and commercialize companion
diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current
and future drug candidates; Blueprint Medicines' ability to
successfully expand its operations, research platform and portfolio
of therapeutic candidates, and the timing and costs thereof;
Blueprint Medicines' ability to realize the anticipated benefits of
its executive leadership transition plan; and the success of
Blueprint Medicines' current and future collaborations,
acquisitions, partnerships or licensing arrangements. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in Blueprint Medicines' filings
with the Securities and Exchange Commission (SEC), including
Blueprint Medicines' most recent Annual Report on Form 10-K, as
supplemented by its most recent Quarterly Report on Form 10-Q and
any other filings that Blueprint Medicines has made or may make
with the SEC in the future. Any forward-looking statements
contained in this report represent Blueprint Medicines' views only
as of the date hereof and should not be relied upon as representing
its views as of any subsequent date. Except as required by law,
Blueprint Medicines explicitly disclaims any obligation to update
any forward-looking statements.
Trademarks
Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated
logos are trademarks of Blueprint Medicines Corporation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-appoints-habib-dable-to-its-board-of-directors-301574460.html
SOURCE Blueprint Medicines Corporation